IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION

IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION

Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BUTLER, Thomas, PALMER, Jim, PAINTER, Edward, UPASANI, Ravi, KELLY, Brendan, WELSCH, Matthew, VEMPATI, Sridhar
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator BUTLER, Thomas
PALMER, Jim
PAINTER, Edward
UPASANI, Ravi
KELLY, Brendan
WELSCH, Matthew
VEMPATI, Sridhar
description Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2023391784A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2023391784A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2023391784A13</originalsourceid><addsrcrecordid>eNrjZDDwDApyDXMNCvZ08nFV8PTz8HTyDPEPClbwd1PwdfXz9NP19fEBioe4Bjk6h3j6-_EwsKYl5hSn8kJpbgZlN9cQZw_d1IL8-NTigsTk1LzUkvjQYCMDI2NjS0NzCxNHQ2PiVAEA5NIngA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION</title><source>esp@cenet</source><creator>BUTLER, Thomas ; PALMER, Jim ; PAINTER, Edward ; UPASANI, Ravi ; KELLY, Brendan ; WELSCH, Matthew ; VEMPATI, Sridhar</creator><creatorcontrib>BUTLER, Thomas ; PALMER, Jim ; PAINTER, Edward ; UPASANI, Ravi ; KELLY, Brendan ; WELSCH, Matthew ; VEMPATI, Sridhar</creatorcontrib><description>Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.</description><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; METALLURGY ; ORGANIC CHEMISTRY</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20231207&amp;DB=EPODOC&amp;CC=US&amp;NR=2023391784A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20231207&amp;DB=EPODOC&amp;CC=US&amp;NR=2023391784A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BUTLER, Thomas</creatorcontrib><creatorcontrib>PALMER, Jim</creatorcontrib><creatorcontrib>PAINTER, Edward</creatorcontrib><creatorcontrib>UPASANI, Ravi</creatorcontrib><creatorcontrib>KELLY, Brendan</creatorcontrib><creatorcontrib>WELSCH, Matthew</creatorcontrib><creatorcontrib>VEMPATI, Sridhar</creatorcontrib><title>IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION</title><description>Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDDwDApyDXMNCvZ08nFV8PTz8HTyDPEPClbwd1PwdfXz9NP19fEBioe4Bjk6h3j6-_EwsKYl5hSn8kJpbgZlN9cQZw_d1IL8-NTigsTk1LzUkvjQYCMDI2NjS0NzCxNHQ2PiVAEA5NIngA</recordid><startdate>20231207</startdate><enddate>20231207</enddate><creator>BUTLER, Thomas</creator><creator>PALMER, Jim</creator><creator>PAINTER, Edward</creator><creator>UPASANI, Ravi</creator><creator>KELLY, Brendan</creator><creator>WELSCH, Matthew</creator><creator>VEMPATI, Sridhar</creator><scope>EVB</scope></search><sort><creationdate>20231207</creationdate><title>IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION</title><author>BUTLER, Thomas ; PALMER, Jim ; PAINTER, Edward ; UPASANI, Ravi ; KELLY, Brendan ; WELSCH, Matthew ; VEMPATI, Sridhar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2023391784A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2023</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><toplevel>online_resources</toplevel><creatorcontrib>BUTLER, Thomas</creatorcontrib><creatorcontrib>PALMER, Jim</creatorcontrib><creatorcontrib>PAINTER, Edward</creatorcontrib><creatorcontrib>UPASANI, Ravi</creatorcontrib><creatorcontrib>KELLY, Brendan</creatorcontrib><creatorcontrib>WELSCH, Matthew</creatorcontrib><creatorcontrib>VEMPATI, Sridhar</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BUTLER, Thomas</au><au>PALMER, Jim</au><au>PAINTER, Edward</au><au>UPASANI, Ravi</au><au>KELLY, Brendan</au><au>WELSCH, Matthew</au><au>VEMPATI, Sridhar</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION</title><date>2023-12-07</date><risdate>2023</risdate><abstract>Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_US2023391784A1
source esp@cenet
subjects CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
title IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T20%3A47%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BUTLER,%20Thomas&rft.date=2023-12-07&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2023391784A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true